Multiscale modeling of the spatial structure of stem cells in neuroblastoma patient-derived tumoroids reveals a critical role for a short-range diffusive process
Bernard, S., Broutier, L. et al.
Paper
Details
#NeuroblastomaResearch #StemCellBiology #MultiscaleModeling

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma | Nature Medicine In a phase 1 clinical trial open to accrual from 2004 to 2009, we treated children with neuroblastoma with Epstein–Barr virus (EBV)-specific T lymphocytes and CD3-activated T cells—each expressing chimeric antigen receptors (CARs) targeting GD2 but without an embedded co-stimulatory sequence (first-generation CARs). These CARs incorporated barcoded sequences to track each infused population. We previously reported outcomes up to 5 years and now report long-term outcomes up to 18 years. Of 11 patients with active disease at infusion, three achieved a complete response that was sustained in two patients, one for 8 years until lost to follow-up and one for more than 18 years. Of eight patients with no evidence of disease at the time of CAR-T administration, five are disease free at their last follow-up between 10 years and 15 years after infusion. Intermittent low levels of transgene were detected during the follow-up period with significantly greater persistence in those who were long-te

Long-term study of GD2-directed CAR-T cell therapy in neuroblastoma shows sustained outcomes: 18-year follow-up from a 2004-2009 Phase 1 trial. #NeuroblastomaResearch PMID:39962287, Nat Med 2025, @NatureMedicine https://doi.org/10.1038/s41591-025-03513-0 #Medsky 🧪